Core Insights - NuCana plc has received a significant patent from the China National Intellectual Property Administration (CNIPA) for NUC-7738, enhancing its global intellectual property strategy and addressing unmet needs in cancer therapies in China [1][2] - NUC-7738 is currently in a Phase 1/2 clinical study (NuTide:701) in combination with pembrolizumab for patients with PD-1 inhibitor refractory or resistant melanoma, with encouraging clinical data reported [1][2] - The company aims to expand the NuTide:701 study and reinforce the overall data package to provide new treatment options for cancer patients [2] Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, which transforms conventional chemotherapy agents into more effective and safer medicines [3] - The company's pipeline includes NUC-7738, which disrupts RNA polyadenylation and targets multiple aspects of the tumor microenvironment, and NUC-3373, derived from the nucleoside analog 5-fluorouracil [3] - NUC-3373 is being evaluated in a Phase 1b/2 modular study in combination with pembrolizumab and docetaxel for advanced solid tumors and lung cancer, respectively [3]